Novartis to acquire kidney disease biotech Chinook for up to $3.5B

Novartis has agreed to acquire Chinook Therapeutics for as much as $3.5 billion, taking a chance that a pair of kidney disease drugs the biotechnology company has developed will succeed in late-stage testing.